Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation. Evidence-based clinical science should guide FDA decision making about product labeling

Lee P. Shulman*, Louise H. Bateman, Mitchell D. Creinin, Vanessa E. Cullins, Lee Lee Doyle, Emily Godfrey, Patricia Murphy, Pablo Rodriguez, Scott J. Spear, Felicia H. Stewart, Michael A. Thomas, Carolyn L. Westhoff, Sandra Worthington

*Corresponding author for this work

Research output: Contribution to journalComment/debate

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)440-442
Number of pages3
JournalContraception
Volume73
Issue number5
DOIs
StatePublished - May 2006

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Shulman, L. P., Bateman, L. H., Creinin, M. D., Cullins, V. E., Doyle, L. L., Godfrey, E., Murphy, P., Rodriguez, P., Spear, S. J., Stewart, F. H., Thomas, M. A., Westhoff, C. L., & Worthington, S. (2006). Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation. Evidence-based clinical science should guide FDA decision making about product labeling. Contraception, 73(5), 440-442. https://doi.org/10.1016/j.contraception.2006.01.007